Source: GlobeNewswire

Press Release: BDSI : BioDelivery Sciences to Report First Quarter 2019 Financial Results

RALEIGH, N.C., April 25, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial stage specialty pharmaceutical company dedicated to patients living with chronic pain, today announced that it will report its first quarter 2019 financial results after the close of the U.S. financial markets on Monday, May 6, 2019. The company will host a conference call at 4:30 PM Eastern Time to discuss the results and provide an update on business operations.

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Based on data from BDSI's latest SEC filings

Annual Revenue

Based on data from BDSI's latest SEC filings

Employees

Herm Cukier's photo - CEO of BDSI

CEO

Herm Cukier

CEO Approval Rating

84/100

BioDelivery is a pharmaceutical company that primarily focuses on developing medicines for pain management and addiction... Read more